Crossmark

Frequency and influence of “not relevant” responses on the Dermatology Life Quality Index among adults with atopic dermatitis

Published Online: 2021-02-04

Published Print: 2021-06

Authors

Barbieri, John S. https://orcid.org/0000-0002-5467-4102
Chiesa Fuxench, Zelma C.

Shin, Daniel B.

Takeshita, Junko
Funding

Funding for this research was provided by:

National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32-AR-007465, NIAMS K23-AR068433)
License Information

Text and Data Mining valid from 2021-02-04

Version of Record valid from 2021-02-04
More Information

Article History

Accepted: 15 January 2021

First Online: 4 February 2021

Compliance with ethical standards

:

: Dr. Takeshita receives a research grant from Pfizer Inc (to the Trustees of the University of Pennsylvania) for work that is unrelated to this study and has received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly. Dr. Chiesa Fuxench has served as a consultant for the National Eczema Association, Asthma and Allergy Foundation, Sanofi, Pfizer, and AbbVie receiving honoraria, and receives or has received research grants (to the Trustees of the University of Pennsylvania) from Regeneron, Sanofi, Leo, Menlo Therapeutics, Tioga and Vanda pharmaceuticals for clinical trials related to atopic dermatitis; and has received payment for continuing medical education work related to atopic dermatitis that was supported indirectly by Sanofi and Regeneron.

: This study was deemed exempt by the University of Pennsylvania Institutional Review Board.

Document is current